{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000035","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-11-10T21:36:23+00:00","discovered_at":"2026-11-10T21:37:00.237349+00:00","generated_at":"2026-11-10T21:37:05.357624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio Q1 FY2027 revenue rises to $1.1M; IBIO-600 SAD dosing complete, IBIO-610 IND due end-2026","bullets":["Revenue of ~$1.1M vs $0.1M a year earlier; R&D $6.7M (+87% YoY) on IBIO-600 Phase 1, NHP studies and CMC; G&A $2.8M (+10%).","Cash, cash equivalents and investments in debt securities totaled ~$76.7M as of September 30, 2026.","IBIO-610 NHP data at EASD: fat was 93% of weight lost with semaglutide combo vs 77% for semaglutide alone; lean mass 6% vs 22%.","IBIO-600 Phase 1 single ascending dose dosing complete; interim SAD data and start of multiple ascending dose portion expected in Q1 2027.","iBio targets an IND-equivalent filing for IBIO-610 by end of 2026 and first-in-human studies in the first half of 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000035","json":"https://secwatch.observer/filing/0001420720-26-000035.json","markdown":"https://secwatch.observer/filing/0001420720-26-000035.md","text":"https://secwatch.observer/filing/0001420720-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/0001420720-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/ibio-20261110x8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:37:05.357624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}